Guilin Sanjin(SZ:002275) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-04-10 22:54Summary of Key Points Core Viewpoint - Guilin Sanjin Pharmaceutical Co., Ltd. plans to provide a guarantee for its wholly-owned subsidiary, Baifan Biotechnology (Shanghai) Co., Ltd., for an increased credit limit of 8 million RMB, which is within the expected guarantee limit for the fiscal year 2024 [1][2]. Group 1: Guarantee Overview - The company approved a total guarantee amount not exceeding 200 million RMB for its subsidiaries, including Baofan Biotechnology and Baifan Biotechnology, during board meetings held on April 24, 2024, and the annual shareholders' meeting on May 16, 2024 [1][2]. - The guarantee for Baifan Biotechnology is capped at 150 million RMB, while Baofan Biotechnology is capped at 50 million RMB [1][2]. Group 2: Actual Guarantee Situation - As of the announcement date, the actual guarantee balance for the company and its subsidiaries is 266.15 million RMB, accounting for 9.45% of the latest audited net assets [7]. - The actual guarantee balance for Baifan Biotechnology is 168.60 million RMB, representing 5.99% of the latest audited net assets [7]. Group 3: Contractual Details - The company signed a maximum guarantee contract with CITIC Bank Guilin Branch, agreeing to provide joint liability guarantee for Baifan Biotechnology's credit increase from 12 million RMB to 20 million RMB [3][4]. - The guarantee period for the contract is three years from the maturity date of the main contract obligations [6]. Group 4: Additional Information - The remaining available guarantee limit for Baifan Biotechnology after this guarantee will be 30 million RMB [5]. - The company has not provided guarantees to any entities outside the consolidated financial statements and has no overdue debts related to guarantees or litigation amounts [7].